What this study adds?
Ropeginterferon alfa-2b is a novel pegylated interferon with superior
pharmacokinetic parameters than the marketed pegylated interferon
product, allowing biweekly injection.
Ropeginterferon alfa-2b has better safety profiles than the marketed
pegylated interferon product.